This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to telisotuzumab adizutecan prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Exclusion Criteria:

• There are other suitable treatment options.
• The participant qualifies for ongoing clinical trials.